Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...

More documents

Recommendations

Info

Class of Drug 10 ANTIDEPRESSANTS Substrate class SSRI SNRI 5HT antagonist Drug Brand name (non exhaustive list, generics not listed). For a complete list, please consult www.bcfi.be or www.cbip.be Sertraline Serlain ® Potential Interaction Fluoxetine Prozac ® , Fluoxone ® , Fontex ® Liverpool University (*) / Extra-information Potential Interaction Fluvoxamine Floxyfral ® Potential Interaction Duloxetine Cymbalta ® Potential Interaction Venlafaxine Effexor ® , Venlasand ® Potential Interaction Mirtazapine Remergon ® Potential Interaction May [Sertaline], clinically significant effect on BOC exposure unlikely* Could BOC exposure* Duloxetine clearance reduced in case of moderate hepatic disease, use with caution* May [venlafaxine]* May [mirtazapine]* Recommendations SmPC/ Scientific Literature Cautions in case of hepatic impairment. Sertaline should not be used in patients with hepatic impairment* Lower or less frequent Fluoxetine dose to be considered in case of hepatic insufficiency* CYP pathway(s) (www.cbip/bcfi.be) (www.mims.com.au) CYP2D6 CYP2C9 / CYP2C19 / CYP2D6 / CYP3A4 CYP1A2 / CYP2C9 / CYP2C19 / CYP2D6 / CYP3A4 Use with caution* CYP1A2 / CYP2D6 50% dose reduction required for mild to moderate hepatic insufficiency. More than 50% reduction for patients with cirrhosis. $ CYP2D6, CYP3A4 CYP1A2 / CYP2D6 / CYP3A4 CYP3A4 Substrate/ Inhibitor/ Inducer Inhibitor Inhibitor Substrate
Class of Drug 11 ANxIOLyTICS / SEDATIVES/HyPNOTICS Substrate class Drug Brand name (non exhaustive list, generics not listed). For a complete list, please consult www.bcfi.be or www.cbip.be Alprazolam Xanax ® , Alpraz ® Potential Interaction Diazepam Valium ® Potential Interaction Lorazepam Temesta ® , Lorazetop ® , Serenase ® Liverpool University (*) / Extra-information Not Clinically Significant Midazolam IV Dormicum ® Potential Interaction May [alprazolam]* Recommendations SmPC/ Scientific Literature Close monitoring, lower dose of alprazolam should be considered* May [diazepam]* Use with caution as there is an increased risk of prolonged sedation and respiratory depression* May [midazolam], AUC increase by 3,4 fold, Cmax Status Quo* Lower dose of midazolam IV by 50% (by half)* Close clinical monitoring for respiratory depression and/ or prolonged sedation should be exercised during co-administration of BOC with intravenous midazolam. Dose adjustment of the benzodiazepine should be considered † . smpc: Close clinical monitoring for respiratory depression and/ or prolonged sedation should be exercised during co-administration of BOC with intravenous midazolam. Dose adjustment of the benzodiazepine should be considered Kiser et al., hepatology 2012: Oral midazolam should not be used with BOC, but halving the dose of IV midazolam could be considered with monitoring for therapeutic and toxic effects Midazolam oral Dormicum ® Contraindicated † Contraindicated † Do not co-administer † Kiser et al., hepatology 2012: BOC increases the AUC of oral 0-12 midazolam by 430% (5,3 fold) Oxazepam Oxazepam generics Not Clinically Significant Triazolam IV Halcion ® Coadministration contraindicated May [triazolam] Close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised during co-administration of BOC with intravenous triazolam. Dose adjustment of the benzodiazepine should be considered † smpc: Close clinical monitoring for respiratory depression and/ or prolonged sedation should be exercised during co-administration of BOC with intravenous triazolam. Dose adjustment of the benzodiazepine should be considered CYP pathway(s) (www.cbip/bcfi.be) (www.mims.com.au) CYP3A4 Substrate/ Inhibitor/ Inducer CYP3A4 Substrate CYP1A2 / CYP2C19 / CYP3A4 Substrate CYP3A4 Substrate CYP3A4 Substrate CYP3A4 Substrate CYP3A4 Substrate
Page 1 and 2: Updated version: March 2013 Drug Dr
Page 3 and 4: 3 Legend No clinically significant
Page 5 and 6: Class of Drug 5 OPIOID SUBSTITUTION
Page 7 and 8: Class of Drug 7 ANTICONVULSANTS Sub
Page 9: Class of Drug 9 ANTIDEPRESSANTS Sub
Page 13 and 14: Class of Drug 13 ACEI (ANGIOTENSIN
Page 15 and 16: Class of Drug 15 DIURETICS CALCIUM
Page 17 and 18: Class of Drug 17 ANTICOAGULANTS FIB
Page 19 and 20: Class of Drug 19 STATINS Substrate
Page 21 and 22: Class of Drug 21 HyPOGLyCAEMIC AGEN
Page 23 and 24: Class of Drug 23 IMMUNOSUPPRESSANTS
Page 25 and 26: Class of Drug 25 ANTIBIOTICS Substr
Page 27 and 28: Class of Drug 27 CONTRACEPTIVES Sub
Page 29 and 30: Class of Drug 29 ANTIRETROVIRALS Su
Page 31 and 32: Class of Drug 31 ANTI HEP.B/HEP.C D
Page 33 and 34: 33 No clinically significant intera
Page 35 and 36: disorders Adverse Reactions Common:
Page 37 and 38: Etravirine* (etravirine 200 mg ever
Page 39 and 40: sedatives Midazolam* (oral administ

Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?